Trials / Terminated
TerminatedNCT05760703
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
Phase Ib/II: Multicenter, Open, Dose-escalation Evaluation of the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B Treated With Oral Antiviral Therapy(Long-term Follow-up)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy(Long-term follow-up).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STSG-0002 Injection | Intravenous infusion |
Timeline
- Start date
- 2023-04-25
- Primary completion
- 2023-12-11
- Completion
- 2023-12-11
- First posted
- 2023-03-08
- Last updated
- 2023-12-19
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05760703. Inclusion in this directory is not an endorsement.